Statement Of Cash Flows

Cyfuse Biomedical K.K. - Filing #7345925

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2021-12-31
Statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-586,187,000 JPY
-471,953,000 JPY
Depreciation
38,122,000 JPY
54,285,000 JPY
Interest expenses
9,774,000 JPY
7,457,000 JPY
Foreign exchange losses (gains)
JPY
4,000 JPY
Decrease (increase) in trade receivables
-3,535,000 JPY
44,108,000 JPY
Decrease (increase) in inventories
-5,646,000 JPY
21,368,000 JPY
Increase (decrease) in trade payables
-1,918,000 JPY
-5,077,000 JPY
Subtotal
-678,354,000 JPY
-400,956,000 JPY
Other, net
-16,629,000 JPY
281,000 JPY
Income taxes paid
-2,441,000 JPY
-2,009,000 JPY
Net cash provided by (used in) operating activities
-562,296,000 JPY
-403,596,000 JPY
Interest paid
-9,735,000 JPY
-7,453,000 JPY
Cash flows from operating activities
Increase (decrease) in accounts payable - other
-13,246,000 JPY
13,477,000 JPY
Cash flows from operating activities
Cash flows from investing activities
Purchase of property, plant and equipment
-19,474,000 JPY
-228,276,000 JPY
Net cash provided by (used in) investing activities
-19,474,000 JPY
-430,674,000 JPY
Cash flows from facilities maintenance and investing activities
Cash flows from financing activities
Proceeds from issuance of shares
22,880,000 JPY
2,328,247,000 JPY
Proceeds from long-term borrowings
JPY
90,000,000 JPY
Repayments of long-term borrowings
-77,824,000 JPY
-81,420,000 JPY
Net cash provided by (used in) financing activities
18,236,000 JPY
2,658,538,000 JPY
Net increase (decrease) in cash and cash equivalents
-563,534,000 JPY
1,824,267,000 JPY
Cash and cash equivalents
2,873,773,000 JPY
3,437,307,000 JPY
1,613,040,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.